170 178

Cited 0 times in

Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment

DC Field Value Language
dc.contributor.author강석민-
dc.contributor.author오재원-
dc.contributor.author이승현-
dc.contributor.author이찬주-
dc.date.accessioned2022-01-26T01:58:38Z-
dc.date.available2022-01-26T01:58:38Z-
dc.date.issued2021-05-
dc.identifier.issn1738-5520-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/187421-
dc.description.abstractResults from cardiovascular outcome trials (CVOT) with 5 different sodium-glucose co-transporter 2 inhibitors (SGLT2i; empagliflozin, canagliflozin, dapagliflozin, ertugliflozin, sotagliflozin), initially developed for their glucose-lowering effect by blocking tubular glucose reabsorption in kidney, have been shown to decrease the risk of heart failure hospitalization (HFH) across a range of patients with and without atherosclerotic cardiovascular disease in patients with type 2 diabetes mellitus (T2DM). Following these CVOT results, SGLT2i (dapagliflozin, empagliflozin, sotagliflozin) also were reported to reduce HFH and cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF), regardless of existence or absence of T2DM. Ongoing studies have been conducted to evaluate the clinical benefit of SGLT2i (empagliflozin, dapagliflozin) in patients with heart failure with preserved ejection fraction (HFpEF). Although SGLT2i brought us to the entrance of a new era for prevention of HF incidence and worsening of HF, the search for pivotal mechanism of SGLT2i to improve our pharmacological armamentarium should continue in order to protect every HF patient from fatal progression of HF disease. In this review, we summarized the updated clinical evidences on SGLT2i (rather than basic and translational evidence) for reduction of HF risk in T2DM patients and favorable clinical outcomes in both HFrEF and HFpEF patients.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish, Korean-
dc.publisherKorean Society of Circulation-
dc.relation.isPartOfKOREAN CIRCULATION JOURNAL-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleSodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorJaewon Oh-
dc.contributor.googleauthorSeung Hyun Lee-
dc.contributor.googleauthorChan Joo Lee-
dc.contributor.googleauthorSeok Min Kang-
dc.identifier.doi10.4070/kcj.2021.0070-
dc.contributor.localIdA00037-
dc.contributor.localIdA02395-
dc.contributor.localIdA02932-
dc.contributor.localIdA03238-
dc.relation.journalcodeJ01952-
dc.identifier.eissn1738-5555-
dc.identifier.pmid33975387-
dc.subject.keywordHeart failure-
dc.subject.keywordSodium-glucose cotransporter-
dc.subject.keywordType 2 diabetes-
dc.contributor.alternativeNameKang, Seok Min-
dc.contributor.affiliatedAuthor강석민-
dc.contributor.affiliatedAuthor오재원-
dc.contributor.affiliatedAuthor이승현-
dc.contributor.affiliatedAuthor이찬주-
dc.citation.volume51-
dc.citation.number5-
dc.citation.startPage399-
dc.citation.endPage408-
dc.identifier.bibliographicCitationKOREAN CIRCULATION JOURNAL, Vol.51(5) : 399-408, 2021-05-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Biochemistry and Molecular Biology (생화학-분자생물학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.